EUVIMEDEUVIMED entdecken
Delphi-StudieOpen Access · CC BY-NC 4.0

The role of osimertinib in the therapeutic pathway of EGFR-mutated NSCLC: results from an Italian Delphi Consensus

Andrea Ardizzoni, Ilaria Attili, Federico Cappuzzo iD, Andrea De Giglio iD, Filippo De Marinis iD, Maristella Giammaruco iD, Cesare Gridelli, Vito Ladisa, Federica Maiocchi, Paolo Maione, Silvia Novello iD, Francesco Passiglia iD und 2 weitere

Global and Regional Health Technology Assessment · 04.11.2026 · 13 (1) · 275-292

DOI: 10.33393/grhta.2026.4055 ↗

Kurz gefasst

Delphi-Studie in der Zeitschrift Global and Regional Health Technology Assessment, online erschienen am 04.11.2026. Verfasst von Andrea Ardizzoni und 13 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna - Italy. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Osimertinib has become a key therapeutic option across multiple disease settings in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC), supported by evidence from the AURA3, FLAURA, ADAURA, FLAURA2, and LAURA trials. However, uncertainties remain regarding its impact on quality of life (QoL), tolerability, and positioning as standard of care in clinical practice. This study assessed agreement among Italian experts on the role of osimertinib across the therapeutic continuum of EGFR-mutated NSCLC using a Delphi consensus methodology.

Methods

An 11-member Steering Committee developed and validated 35 statements covering four domains: standard of care, QoL, treatment manageability and adverse event management. The statements were evaluated through a two-round Delphi survey by an Italian Expert Panel of 28 clinicians experienced in managing EGFR-mutated NSCLC. Consensus was defined as ≥ 70% agreement (Likert scores 4-5).

Results

Among the initial 26 statements, the completion rate was 100% across both rounds, with consensus achieved for all statements. For the additional 9 statements, the completion rate was 89.3%, and consensus was again reached for all statements. High agreement supported osimertinib as a standard therapeutic option in advanced, adjuvant and unresectable stage III EGFR-mutated NSCLC. Experts also recognized its favorable impact on central nervous system disease control, QoL, treatment tolerability and long-term clinical manageability.

Conclusion

This Italian Delphi Consensus confirms broad expert agreement on the central role of osimertinib across the therapeutic continuum of EGFR-mutated NSCLC, supporting its use as a standard of care in multiple clinical settings.

Schlagwörter

Stichwörter der Autor:innen

Adverse eventsDelphi ConsensusEGFR-mutated NSCLCOsimertinibQuality of lifeStandard of care

Autor:innen und Institutionen

  • Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna - Italy.
  • Division of Thoracic Oncology, European Institute of Oncology (IEO), IRCCS, Milano - Italy.
  • Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Roma - Italy.
  • Division of Medical Oncology, S.G. Moscati Hospital, Avellino - Italy.
  • Department of Hospital Pharmacy, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano - Italy.
  • More Than Access S.r.l. Società Benefit, Milano - Italy.

ORCID-Profile: Federico Cappuzzo, Andrea De Giglio, Filippo De Marinis, Maristella Giammaruco, Silvia Novello, Francesco Passiglia, Edoardo Sanna, Roberto Ravasio

Zitieren

APA

Ardizzoni, A., Attili, I., Cappuzzo, F., De Giglio, A., De Marinis, F., Giammaruco, M., Gridelli, C., Ladisa, V., Maiocchi, F., Maione, P., Novello, S., Passiglia, F., Sanna, E., & Ravasio, R. (2026). The role of osimertinib in the therapeutic pathway of EGFR-mutated NSCLC: results from an Italian Delphi Consensus. Global and Regional Health Technology Assessment, 13(1), 275-292. https://doi.org/10.33393/grhta.2026.4055

Vancouver

Ardizzoni A, Attili I, Cappuzzo F, De Giglio A, De Marinis F, Giammaruco M, et al. The role of osimertinib in the therapeutic pathway of EGFR-mutated NSCLC: results from an Italian Delphi Consensus. Global and Regional Health Technology Assessment. 2026;13(1):275-292. doi:10.33393/grhta.2026.4055

BibTeX
@article{Ardizzoni2026,
  author = {Ardizzoni, Andrea and Attili, Ilaria and Cappuzzo, Federico and De Giglio, Andrea and De Marinis, Filippo and Giammaruco, Maristella and Gridelli, Cesare and Ladisa, Vito and Maiocchi, Federica and Maione, Paolo and Novello, Silvia and Passiglia, Francesco and Sanna, Edoardo and Ravasio, Roberto},
  title = {The role of osimertinib in the therapeutic pathway of EGFR-mutated NSCLC: results from an Italian Delphi Consensus},
  journal = {Global and Regional Health Technology Assessment},
  year = {2026},
  volume = {13},
  number = {1},
  pages = {275--292},
  doi = {10.33393/grhta.2026.4055}
}
Kostenlos starten →